High dose intravenous immunoglobulin g pretreatment: effect on lipid peroxidation and reperfusion injury to the liver.
The aim of this study was to examine the effect of intravenous immunoglobulin G (IVIG) compared with that of gadolinium chloride (GdCl3) in the inhibition of Kupffer cell activation on lipid peroxidation after severe total hepatic ischemia/reperfusion (I/R). Male Wistar rats ( n = 40) were randomly divided into four equal groups: a sham-operation group, a control I/R group, and two I/R groups pretreated with either IVIG or GdCl3 intravenously. Following 60 minutes of total hepatic ischemia and 120 minutes of reperfusion, the rats were sacrificed and liver and blood samples collected. Additional animals ( n = 80) were followed up for survival rate determination. Results showed that I/R decreased the survival rate to 10%, increased the levels of aspartate (AST) and alanine (ALT) transaminase and lactate dehydrogenase (LDH) in serum to 2487, 2189, and 4236 IU/L, respectively, and increased malondialdehyde (MDA) levels in liver to 1.552 nmol/g compared with 1.114 nmol/g in the sham operation group. Pretreatment with GdCl3 increased the survival rate to 50% and decreased the levels of AST, ALT, and LDH in serum to 1496, 1298, and 3245 IU/l, respectively. Pretreatment with IVIG increased the survival rate to 60% and decreased the levels of AST, ALT, and LDH in serum to 449, 367, and 1456 IU/l, respectively, and the levels of MDA in liver to 1.153 and 1.148 nmol/g for GdCl3 and IVIG respectively. Histologic examination showed protection of liver parenchyma in the animals treated with GdCl3 or IVIG.
Giakoustidis
Dimitrios
D
Department of Surgery, Aristotle University of Thessaloniki, "Hippokration" Hospital, 49 Konstantinoupoleos Str., 54642, Thessaloniki, Greece. dgiak@auth.gr
Papageorgiou
George
G
Kostopoulou
Evanthia
E
Iliadis
Stavros
S
Giakoustidis
Alexandros
A
Kontos
Nikolas
N
Tsantilas
Dimitrios
D
Botsoglou
Nikolaos
N
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000494:pharmacology; D005682:Gadolinium / Q000008:administration & dosage* / Q000494:pharmacology; D007074:Immunoglobulin G / Q000008:administration & dosage* / Q000494:pharmacology; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage* / Q000494:pharmacology; D015227:Lipid Peroxidation / Q000187:drug effects*; D008099:Liver / Q000098:blood supply*; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous; D005682:Gadolinium; C038958:gadolinium chloride